Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
01 März 2024 - 8:58PM
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, hosted its second
annual Rare Disease Day event at its headquarters on February 29
and virtually in partnership with Alliance to Cure at eight sites
across the United States to provide resources and support for
Utah’s rare disease community. The event featured speakers from
patient advocacy organizations and biotech and healthcare industry
leaders who all share a goal to accelerate the diagnosis and
improve the care of more than 344,000 Utahns living with a rare
disease.
In the United States, a rare disease is considered a condition
with less than 200,000 patients. More than 10,000 rare diseases are
known, most of which are genetic in nature. An estimated one in 10
people in the United States have a rare disease. Today, 95 percent
of rare diseases have no treatment.
Recursion’s Rare Disease Day event was intended to raise
awareness for rare and undiagnosed diseases and the lifelong impact
they have on patients and their families – while highlighting
progress in diagnosis and treatment discovery. The event recognized
advocates who have been instrumental in building Utah’s rare
disease community and have dedicated themselves to support this
important work.
"This event serves as an important reminder of the strength,
resilience and unrelenting spirit of our rare disease community
here in Utah,” said Aimee Edwards, Executive Director of BioHive.
“Through the power of our BioHive network of 1,600+ life science
and healthcare companies in Utah, we aim to bring hope to patients
and their families impacted by these conditions. We are proud of
the formidable progress made and are fully dedicated to continuing
our efforts until every unmet need in the rare disease community is
addressed."
“There is an urgency for diagnoses, treatment and cures for the
rare disease community,” said Gina Zanik, co-founder and executive
director of Rare and Undiagnosed Network and Vice Chair of the Utah
Rare Disease Advisory Council. “The diagnostic odyssey for someone
with a rare disease takes on average seven years. We must shorten
the length of the diagnostic journey and come together to support
patients and their families throughout the duration.”
Rare Disease Day is an annual observance on the last day of
February. A series of events were held globally to raise awareness,
strengthen the rare disease community, and advocate for needed
changes to improve the lives of the 400 million people around the
world who suffer from these conditions.
Rare disease patients came together at Recursion with the RARE
and Undiagnosed Network (RUN), RARE-X, BioHive, ARUP Laboratories,
BioUtah, the University of Utah and the Rare Disease Advisory
Council (RDAC) for the Rare Disease Day event. The coalition of
organizations represents Utah’s strong collaborative ecosystem
dedicated to coordinating, advocating, and promoting the interest
of those living with rare diseases.
“Recursion was founded to reimagine the drug discovery and
development process with an early focus on rare diseases,” said
Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “The status
quo is failing to meet the needs of millions of patients with rare
diseases. The rapidly growing TechBio industry is harnessing
technologies like artificial intelligence to accelerate the process
of bringing more, better medicines to patients who need them.”
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological, chemical and patient-centric datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology, chemistry and
patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerlyTwitter) and LinkedIn.
- Speakers at Recursion's Rare Disease Day Event
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024